A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease

Movement Disorders

Volumn 29, Issue 4, 2014, Pages 568-573

  Saute, Jonas Alex Morales ^a,b   de Castilhos, Raphael Machado ^b,c   Monte, Thais Lampert ^a,b   Schumacher Schuh, Artur Francisco ^a,b   Donis, Karina Carvalho ^b   D'Ávila, Rui ^b   Souza, Gabriele Nunes ^b   Russo, Aline Dutra ^a   Furtado, Gabriel Vasata ^a   Gheno, Tailise Conte ^a   de Souza, Diogo Onofre Gomes ^a   Portela, Luis Valmor Cruz ^a   Saraiva Pereira, Maria Luiza ^a,b,c   Camey, Suzi Alvez ^a   Torman, Vanessa Bielefeld Leotti ^a   de Mello Rieder, Carlos Roberto ^a,b,d   Jardim, Laura Bannach ^a,b,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c Instituto Nacional de Genética Médica Populacional INAGEMP   (Brazil)

^d UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

Clinical trial; Lithium; Machado Joseph disease; Polyglutamine disorders; Spinocerebellar ataxias

Indexed keywords

LITHIUM CARBONATE; PLACEBO; ENZYME INHIBITOR;

8 METER WALKING TIME; 9 HOLE PEGBOARD TEST; ADULT; ARTICLE; ATAXIA; COMPOSITE CEREBELLAR FUNCTIONAL SCORE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; HUMAN; MACHADO JOSEPH DISEASE; MAJOR CLINICAL STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROLOGICAL EXAMINATION SCORE FOR ASSESSMENT OF SPINOCEREBELLAR ATAXIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCALE FOR THE ASSESSMENT AND RATING OF ATAXIA; SCORING SYSTEM; SPINOCEREBELLAR ATAXIA FUNCTIONAL INDEX; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; MACHADO-JOSEPH DISEASE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; LITHIUM CARBONATE; MACHADO-JOSEPH DISEASE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84898059298     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25803     Document Type: Article

References (29)

1. Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994;8:221-228.
2. Maciel P, Gaspar C, DeStefano AL, et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet 1995;57:54-61.
3. Jardim LB, Pereira ML, Silveira I, et al. Neurologic findings in Machado-Joseph disease: relation with disease duration, subtypes, and (CAG)n. Arch Neurol 2001;58:899-904.
4. Jardim LB, Hauser L, Kieling C, et al. Progression rate of neurological deficits in a 10-year cohort of SCA3 patients. Cerebellum 2010;9:419-428.
5. Durr A, Stevanin G, Cancel G, et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol 1996;39:490-499.
6. Costa M do C, Paulson HL. Toward understanding Machado-Joseph disease. Prog Neurobiol 2012;97:239-257.
7. Carmichael J, Sugars KL, Bao YP, Rubinsztein DC. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem 2002;277:33791-33798.
8. Wood NI, Morton AJ. Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res Bull 2003;61:375-383.
9. Berger Z, Ttofi EK, Michel CH, et al. Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway. Hum Mol Genet 2005;14:3003-3011.
10. Pouladi MA, Brillaud E, Xie Y, et al. NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiol Dis 2012;48:282-289.
11. Watase K, Gatchel JR, Sun Y, et al. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model [serial online]. PLoS Med 2007;4:e182.
12. Jia DD, Zhang L, Chen Z, et al. Lithium chloride alleviates neurodegeneration partly by inhibiting activity of GSK3β in a SCA3 Drosophila model. Cerebellum 2013;12:892-901.
13. Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol Sci 2009;110:14-28.
14. Bijur GN, Jope RS. Opposing actions of phosphatidylinositol 3-kinase and glycogen synthase kinase-3beta in the regulation of HSF-1 activity. J Neurochem 2000;75:2401-2408.
15. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008;105:2052-2057.
16. McColl G, Killilea DW, Hubbard AE, et al. Pharmacogenetic analysis of lithium-induced delayed aging in Caenorhabditis elegans. J Biol Chem 2008;283:350-357.
17. Kwon B, Houpt TA. Phospho-acetylation of histone H3 in the amygdala after acute lithium chloride. Brain Res 2010;1333:36-47.
18. Adityanjee, Munshi KR, Thampy A. The syndrome of irreversible lithium-effectuated neurotoxicity. Clin Neuropharmacol 2005;28:38-49.
19. Bauer PO, Kotliarova SE, Matoska V, et al. Fluorescent multiplex PCR-fast method for autosomal dominant spinocerebellar ataxias screening. Genetika 2005;41:830-837.
20. Kieling C, Rieder CRM, Silva ACF, et al. A neurological examination score for the assessment of spinocerebellar ataxia 3 (SCA3). Eur J Neurol 2008;15:371-376.
21. Schmitz-Hubsch T, Du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006;66:1717-1720.
22. Saute JAM, Donis KC, Serrano-Munuera C, et al. Ataxia rating scales-psychometric profiles, natural history and their application in clinical trials. Cerebellum 2012;11:488-504.
23. Schmitz-Hubsch T, Giunti P, Stephenson DA, et al. SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. Neurology 2008;71:486-492.
24. Du Montcel ST, Charles P, Ribai P, et al. Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment. Brain 2008;131:1352-1361.
25. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965;14:61-65.
26. Fleck MP, Louzada S, Xavier M, et al. Application of the Portuguese version of the abbreviated instrument of quality life WHOQOL-bref. Rev Saude Publica 2000;34:178-183.
27. Gorenstein C, Andrade L. Validation of a Portuguese version of the Beck Depression Inventory and the State-Trait Anxiety Inventory in Brazilian subjects. Braz J Med Biol Res 1996;29:453-457.
28. Guy W. National Institute of Mental Health. ECDEU Assessment Manual for Psychopharmacology, revised. ed. Rockville, MD: National Institute of Mental Health; 1976.
29. Schmitz-Hubsch T, Fimmers R, Rakowicz M, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 2010;74:678-684.